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Objective: To investigate prognostic significance of clinical and pathological stages in patients with locally advanced
rectal carcinoma treated with neoadjuvant chemoradiotherapy (neo-CRT) and total mesorectal excision.
Patients and methods: 210 patients with locally advanced rectal carcinoma (cT3-4 or cN+) treated with neo-CRT
followed by total mesorectal excision. Treatment outcomes were compared according to clinical and pathological
stage. Overall survival (OS), disease free survival (DFS) among patients with different clinical stage and pathological
stage after neo-CRT.
Results: The median follow-up time was 47 months (range, 14–98 months). Clinical T stage was associated with 5 year
OS (p = 0.042) and 5 year DFS (p = 0.014) while clinical N stage was not associated with 5 year OS (p = 0.440), 5 year
DFS (p = 0.711). Pathological T stage was associate with 5 year OS (p = 0.001) and 5 year DFS (p = 0.046); and N stage
was associated with 5 year OS (p = 0.001), 5 year DFS (p = 0.002). The pathological stage was further classified into three
groups: ypT0–2N0 in 91 patients (43.3 %), ypT3–4N0 in 69 patients (32.9 %) and ypT0–4N+ in 50 patients (23.8 %). While
pathological stage (ypT0–2 vs ypT3–4N0 vs ypT0–4N+) was associated with 5 year OS (87.9 %, 75.5 %, 56.7 %,
p = 0.000), 5 year DFS (74.5 %, 77.4 %, 50.5 %, p = 0.003). Multivariate analysis showed that ypN stage was an
independent prognostic factor for patients 5 year DFS.
Conclusions: Pathological stage is strongly associated with treatment outcomes in patients with locally
advanced rectal carcinoma treated with neo-CRT followed by total mesorectal excision, which may be used
as guidance for further individualized treatment.
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outcomeColorectal cancer is the 5th most common malignant
neoplasm in morbidity and mortality in China according
to Globocan 2012. Most majority of patients were diag-
nosed as locally advanced disease, among them 49.9 %
were diagnosed as Duck B stage, and 33.9 % Duck C
stage [1]. In colorectal cancer, the morbidity of rectal
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creativecommons.org/publicdomain/zero/1.0/The treatment strategy “neoadjuvant chemoradiother-
apy (Neo-CRT) plus total mesorectal excision (TME)
and six months adjuvant chemotherapy” has been rec-
ommended as the standard of care for patients with lo-
cally advanced rectal cancer by National Comprehensive
Cancer Network (NCCN) since 2006 [3, 4]. Compared
with postoperative chemoradiotherapy, preoperative che-
moradiotherapy has been demonstrated to improve local
tumor control, reduce treatment-related toxicity, and
improve sphincter preservation [5–8]. The finding that
postoperative pathological stage usually differs from pre-
treatment clinical stage complicates the ability to prog-
nosticate outcome in patients treated with neoadjuvantle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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pathological TNM stage is more closely related to the
prognosis than pretreatment clinical stage in these pa-
tients. Patients with locally advanced rectal cancer may
demonstrate a different treatment response to Neo-CRT
ranging from pathological complete response (pCR) to
resistance to Neo-CRT. Studies have reported that
pathological TNM stage is of prognostic significance in
treatment outcomes after Neo-CRT when compared to
clinical TNM stage. Bujko et al. [12] reported that prog-
nostic effect of adjuvant chemotherapy in patients with
ypT0–4N0 disease after Neo-CRT and TME is not convin-
cing, suggesting that adjuvant chemotherapy should be
given individually according to pathological TNM stage.
The purpose of the study was to investigate treatment
response in patients with locally advanced rectal cancer
treated with Neo-CRT and TME and to compare prog-
nostic effects of clinical and pathological TNM stages.
Materials and methods
From March 2003 to December 2010, 210 patients with
locally advanced rectal cancer (cT3–4 or cN+) were
treated with Neo-CRT followed by TME with or without
adjuvant chemotherapy at the Sun Yat-Sen University
Cancer Center. Diagnosis was pathologically confirmed
prior to Neo-CRT. Pretreatment clinical stage was deter-
mined by physical examination, ultrasound colonoscopy/
colonoscopy, computerized tomography and/or magnetic
resonance imaging.
In the present study, preoperative radiotherapy (RT)
was performed with three-dimensional conformal radi-
ation therapy (3D-CRT) technique with 6–8 MV X-ray
and 3–4 fields at the full pelvis. The target volume defin-
ition was followed by the International Commission of
Radiation Units 50 report recommendations. The delin-
eation of clinical target volume (CTV) included primary
rectal carcinoma, both ends of the affected rectum, the
surrounding tissues of the affected rectum, the mesor-
ectal area, the presacral lymph nodes, the obturator
lymph nodes, and the iliac lymph nodes. For patients
with stage T4 rectal carcinoma with bladder involve-
ment, the delineation of CTV also included external
iliac lymph nodes. The planned target volume (PTV)
was designated as 8–10 mm margin from the CTV. For
the dose prescription was as follows: 100 % of the pre-
scription dose covered at least 95 % of the PTV; 95 % of
the prescription dose covered at least 100 % of the PTV.
The reference point was set as the intersection of the cen-
tral axes of the three or four beams. The median radiation
dose to PTV was 46.0 Gy (ranging from 30.0 to 50.0 Gy),
2 Gy per fraction, 5 fractions per week. The dose to the
OARs was aimed to be as low as possible and must at least
comply with the following constraints: bladder >50Gy
in <50 % volume; Dmean of small bowel < 46Gy, smallbowel > 50Gy in <5 % volume. Five patients who were
operated on R1 or R2 resection were treated with post-
operative radiotherapy with median dose of 36.0 Gy
(range from 30.0 Gy to 40.0 Gy) delivered by 3D-CRT
technique.
Two regimens of chemotherapy were administered dur-
ing radiotherapy either the FOLFOX regimen (Fluorouracil,
3.0 g/m2, IV continuous infusion for 48 h on day 1; Leucov-
orin calcium, 200.0 mg/m2, IV bolus on day 1; Oxaliplatin,
100.0 mg/m2, IV on day 1; two cycles at an interval
of 3 weeks), or the XELOX regiment (Capecitabine,
1000.0 mg/m2, on d1–14; Oxaliplatin, 100.0 mg/m2,
IV on day 1; two cycles at an interval of 3 weeks).
The postoperative adjuvant chemotherapy was either
one of FOLFOX, XELOX or Capecitabine alone with
median cycles of 2 (range from 2 to 6 cycles).
Radical surgery was performed according to the princi-
ples of total mesorectal excision. Postoperative patho-
logical examination was performed according to the
criteria developed by the AJCC/UICC (2002).
Treatment response including tumor regression re-
sponse to Neo-CRT was investigated according to patho-
logical TNM staging classification after radical surgery.
Treatment outcome was analyzed according to clinical
and pathological TNM stages in terms of overall survival
(OS), disease free survival (DFS), local recurrence free
survival (LRFS) and distant metastasis free survival
(DMFS) among patients with different clinical stage
(IIA, IIB, IIIA, IIIB and IIIC) and pathological stage
(ypT0–2N0, ypT3–4N0 and ypT0–4N+).
All statistical analysis was performed using SPSS v17.0
software. p value of <0.05 was considered to be of statis-
tical significance. t-test or the Wilcoxon rank sum test
was used for continuous variables and the chi-square
test for categorical variables. Kaplan-Meier analysis was
performed for clinical outcome, and the log-rank test
was used for comparison between clinical and patho-
logical outcomes curves. Univariate and multivariate
analysis of the prognostic factors were performed using
Cox proportional hazard models.
Results
Patient characteristics
The patient characteristics are shown in Table 1. There
were totally 210 patients including 149 males (71 %) and 61
females (29 %) with a median age of 56 years (range, 15–80
years). Patients with clinical stage IIA, IIB, IIIA, IIIB and
IIIC were 31, 38, 4, 54 and 83, respectively. The median dis-
tance of carcinoma to the anus was 5 cm (1–16 cm). The
median CEA level was 4.5 ng/mL (ranging from 0.2 ng/ml
to 249.6 ng/mL). The tumor location of low-lying (distance
between anal verge and lower edge of tumor ≤ 5 cm),
middle-third (5 cm < distance between anal verge and lower
edge of tumor ≤ 10 cm) and upper-third (distance btw anal





Median age (years, range) 56 (15–80)
Median CEA level prior to treatment
(μg/L, range)
4.5 (0.2–249.6)
Median hemoglobin level prior to treatment
(g/L, range)
128 (64–170)




Median distance btw anal verge and lower
edge of tumor (cm, range)
5.0 (1.0–16.0)
Clinical stage mordalities (N, %)
Transrectal ultrasonograpy 187 (89.0)
CT 160 (76.2)
MRI 21 (10.0)















Concurrent chemotherapy regimen (N, %)
FOLFOX 38 (18.1)
XELOX/Xeloda 164 (78.1)
Other regimen 8 (3.8)
Post-op adjuvant chemotherapy (N, %)
Yes 155 (73.8)
None 55 (26.2)
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78 and 2, respectively.
The median duration from the completion of radiother-
apy to surgery was 42 days (interquartile range, 20–73
days). After Neo-CRT, 97.6 % (205/210 patients) of the pa-
tients were received R0 resection with Mile’s procedure in
102 patients (48.6 %), Dixon procedure in 104 patients
(49.5 %) and Hartmann procedure in 4 patients (1.6 %).
Sphincter preservation was obtained in 75 patients
(42.2 %, 75/177 patients) who were assumed to receive
Miles’ procedure during multidisciplinary evaluation. Dur-
ing the surgery, the median number of dissected lymph
nodes was 6 (range, 0–37). The pathological stage was
classified into ypT0–2N0 in 91 patients (43.3 %) with
complete pathologic response in 52 patients (24.8 %),
ypT3–4N0 in 69 patients (32.9 %) and ypT0–4N+ in 50
patients (23.8 %).
Five patients who were operated on R1 or R2 resection
due to bladder/prostate involvement received postopera-
tive radiotherapy with median dose of 36 Gy (range from
30 to 40 Gy) delivered by 3D-CRT technique. Among
patients with ypT0–4N0 (160 patients), 115 received
postoperative chemotherapy.
The complication after radical surgery included post-
poned incisions heal in 7 patients (3.3 %), wound infec-
tion in 2 patients (1.0 %), anastomotic leak in 2 patients
(1.0 %) and pelvic sepsis in 1 patient. All of them were
healed with best supportive care. The artificial anus was
unobstructed.
Patient outcome after Neo-CRT
The median follow-up was 47 months (range, 14–98
months). The 5 year OS and DFS for the whole group
were 77.1 % and 70.4 %, respectively. The rates of local
tumor recurrence and distant metastasis at 5 year were
7.1 % and 20.0 %, respectively. In the present study, there
were 155 patients received post-op adjuvant chemother-
apy, 55 patients did not. The 5 year OS, DFS, LRFS and
DMFS for these two groups were 79.8 % and 69.2 % (p =
0.085), 73.5 % and 60.6 % (p = 0.072), 91.5 % and 89.5 %
(p = 0.629) and 82.8 % and 71.2 % (p = 0.106), respectively.
The 5 year LRFS in patients with low-lying, middle-third
and upper-third rectal carcinoma was 87.1 %, 97.3 % and
100 %, respectively (p = 0.039).
Eleven patients developed single locoregional tumor
recurrence that occurred at the first 3 years; 2 developed
locoregional tumor recurrence and distant metastasis in
the lung or bone; 29 patients developed distant metastasis
with 14 in the lung, 11 in the liver, 2 in the bone, other 2
in the the abdominal or supraclavicular lymphadenopathy.
Among them, 5 showed recurrence at the primary site, 4
at the iliac, 2 at the perirectal region, one at the primary
site with lung metastasis and the other one at the iliac
with lung and bone metastases. Twenty-nine patients
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Among them, 14 patients showed distant metastasis at the
lung, 11 at the liver, 2 at the bone, and 2 at lymph nodes
at other site.
Five patients who were treated with Neo-CRT of
46 Gy and operated on R1 or R2 resection due to blad-
der/prostate involvement received postoperative radio-
therapy with median dose of 36 Gy. Two of them died
of the disease and the other 3 remains disease free
survival.
At the end of the study, 43 patients had died (20.4 %)
of recurrent or metastatic disease in the lung, liver and
locoregional recurrence.Comparison of change between clinical and pathological
stages after Neo-CRT
After Neo-CRT, postoperative pathological evaluation
according to TNM classification in comparison with
clinical stage showed that T stage decreased in 153 pa-
tients (72.9 %), and increased in 5 (2.4 %), and remained
unchanged in 52 (24.8 %); N stage decreased in 116 pa-
tients (55.2 %), increased in 13 patients (6.2 %),
remained unchanged in 20 patients with clinically posi-
tive lymph nodes (9.5 %) and 61 (29.0 %) with clinically
negative lymph nodes.
After Neo-CRT, postoperative pathological evaluation ac-
cording to TNM classification showed T downstage in 153Fig. 1 Kaplan-Meier overall survival a, b stratified by clinical T and N stage
with neo-adjuvant chemoradiotherapy and total mesorectal excisionpatients (72.9 %), N downstage in 116 patients (55.2 %) and
pathological TNM downstage in 132 patients (62.9 %).
Correlation of clinical stage with patient outcome
In regards to the prognosis of patients with different
clinical T stages in Fig. 1, the 5 year OS was 100 %,
86.1 %, and 70.7 % in patients with cT1–2, cT3, and cT4
rectal carcinoma, respectively (p = 0.042); the 5 year DFS
was 100 %, 79.7 % and 68.7 % in patients with cT1–2,
cT3, and cT4 rectal carcinoma, respectively (p = 0.014).
The 5 year OS was 79.5 % and 75.6 % in patients with
stage cN0 and cN+ rectal carcinoma, respectively (p =
0.440); the 5 year DFS was 66.2 % and 69.2 % in patients
with stage cN0 and cN+ rectal carcinoma, respectively
(p = 0.711).
For patients with clinical IIA, IIB, IIIA, IIIB and IIIC
rectal carcinoma, the 5 year OS was 80.1 %, 79.0 %,
100.0 %, 74.4 % and 74.6 %, respectively (p = 0.661). The
5 year DFS was 74.2 %, 69.5 %, 100.0 %, 69.2 %, 66.2 %,
respectfully (p = 0.662). The 5 year LRFS was 93.5 %,
86.6 %, 100.0 %, 96.2 % and 88.6 %, respectively (p =
0.361). The 5 year DMFS was 80.5 %, 86.5 %, 100.0 %,
72.5 % and 78.8 %, respectively (p = 0.241).
Correlation of pathological stage with patient outcome
As shown in Fig. 2 for the prognosis of patients with dif-
ferent pathological TN stages, the 5 year OS was 88.6 %
and 66.2 % in patients with ypT0–2 and ypT3–4 rectalin patients with locally advanced rectal carcinoma who were treated
Fig. 2 Kaplan-Meier overall survival a, b stratified by pathological T and N stage in patients with locally advanced rectal carcinoma who were
treated with neo-adjuvant chemoradiotherapy and total mesorectal excision
Fig. 3 Kaplan-Meier overall survival stratified by pathological TN
stage in patients with locally advanced rectal carcinoma who were
treated with neo-adjuvant chemoradiotherapy and total
mesorectal excision
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75.0 % and 65.6 % in patients with ypT0–2 and ypT3–4
rectal carcinoma, respectively (p = 0.002). The 5 year OS
was 82.8 % and 59.9 % in patients with ypN0 and ypN+
rectal carcinoma, respectively (p = 0.001); the 5 year DFS
was 76.7 % and 54.1 % in patients with ypN0 and ypN+
rectal carcinoma, respectively (p = 0.002).
The pathological stage was further classified into three
groups: ypT0–2N0 (91 patients, 43.3 %), ypT3–4N0 (69
patients, 32.9 %) and ypT0-4N+ (50 patients, 23.8 %).
The 5 year OS for groups 5 year OS for groups of
ypT0–2N0, ypT3–4N0 and ypT0–4N+ was 87.9 %,
75.5 % and 56.7 % (p = 0.000), respectively; the 5 year
DFS was 74.5 %, 77.4 % and 50.5 % (p = 0.003), respect-
ively. In regards to the prognosis of patients with ypT0–
2 and ypT3–4 rectal carcinoma, as shown in Fig. 3, the
5 year OS for patients with was 88.7 % and 66.1 % (p =
0.001), respectively; and the 5 year DFS was 75.5 % and
65.6 %, respectively (p = 0.046).
Univariate analysis and multivariate analysis of
prognostic factors for patients with locally advanced
rectal carcinoma
Univariate analysis (Table 2) showed that pT, pN and
pathological stages were associated with OS, DFS, LRFS
and DMFS after Neo-CRT for patients with locally ad-
vanced rectal carcinoma. Clinical T stage was associated
with DFS and distance between anal verge and lower
edge of tumor was associated with LRFS. Multivariateanalysis (Table 3) showed that only ypN stage was an in-
dependent prognostic factor for OS, DFS, LRFS and
DMFS; ypT was associated with OS and DMFS. Patients
with pN+ disease showed a high recurrence rate than
those with pN0 disease (HR: 2.239;95 % CI:1.286–3.898).
Table 2 Univariate analysis of prognostic factors for patients with locally advanced rectal carcinoma
Variable OS DFS LRFS DMFS
HR p value 95 % CI HR p value 95 % CI HR p value 95 % CI HR p value 95 % CI
Pathological stage
ypT0–2N0 1 1 1 1
ypT3–4N0 2.076 0.074 0.933–4.622 1.031 0.925 0.547–1.942 1.279 0.508 0.617–2.651 1.519 0.317 0.670–3.444
ypT0–4N+ 3.688 0.001 1.702–7.911 2.255 0.007 1.246–4.081 2.816 0.003 1.429–5.546 3.429 0.002 1.602–7.339
pT stage
ypT3–4 vs. ypT0–2 3.131 0.001 1.578–6.212 1.675 0.049 1.001–2.801 1.970 0.025 1.090–3.561 2.615 0.005 1.328–5.150
pN stage
ypN+ vs. ypN0 2.595 0.002 1.414–4.760 2.252 0.004 1.333–3.804 2.519 0.002 1.411–4.498 2.889 0.001 1.540–5.420
Sex
Female vs. Male 0.950 0.879 0.488–1.850 0.943 0.838 0.539–1.652 0.894 0.730 0.473–1.690 1.060 0.867 0.538–2.087
Age, years
>56 vs. ≤56 1.243 0.477 0.682–2.266 1.243 0.396 0.752–2.056 1.433 0.215 0.812–2.532 1.444 0.248 0.774–2.695
Pretreatment CEA level, μg/L
≥5.0 vs. <5.0 0.868 0.648 0.474–1.592 0.941 0.816 0.566–1.565 1.145 0.640 0.650–2.018 1.282 0.434 0.689–2.385
Pretreatment Hb level, g/L
Anemia vs. normal 1.092 0.815 0.521–2.289 1.047 0.888 0.554–1.976 1.225 0.558 0.622–2.412 1.020 0.960 0.469–2.220
Distance btw anal verge and lower edge of tumor, cm
≤5.0 vs. >5.0 1.294 0.429 0.683–2.449 1.643 0.082 0.939–2.877 5.446 0.023 1.257–23.586 0.907 0.761 0.481–1.707
Differentiation of tumor
Well–vs. poorly differentiated 1.315 0.126 0.926–1.869 1.198 0.246 0.883–1.624 1.124 0.519 0.788–1.601 1.198 0.345 0.823–1.744
cT stage
cT4 vs. cT1–3 1.837 0.074 0.943–3.577 1.856 0.030 1.060–3.249 1.735 0.083 0.931–3.233 1.648 0.148 0.838–3.241
cN stage
cN+ vs. cN0 1.291 0.444 0.671–2.484 1.107 0.712 0.646–1.897 1.150 0.654 0.624–2.121 1.473 0.278 0.732–2.966
Post–op adjuvant chemotherapy












Table 3 Multivariate analysis of prognostic factors for patients with locally advanced rectal carcinoma
Variable OS DFS LRFS DMFS
HR p value 95 % CI HR p value 95 % CI HR p value 95 % CI HR p value 95 % CI
pN stage
ypN+ vs. ypN0 2.206 0.016 1.159–4.196 2.239 0.004 1.286–3.898 2.239 0.003 1.286–3.898 2.678 0.004 1.374–5.218
pT stage
ypT3–4 vs. ypT0–2 2.640 0.007 1.308–5.331 1.441 0.175 0.850–2.443 1.621 0.121 0.880–2.987 2.196 0.027 1.096–4.400
Sex
Female vs. Male 0.859 0.663 0.433–1.702 0.861 0.605 0.487–1.522 0.794 0.486 0.414–1.520 0.924 0.824 0.461–1.853
Age, years
>56 vs. ≤56 1.382 0.298 0.752–2.539 1.389 0.208 0.833–2.315 1.679 0.081 0.939–3.004 1.683 0.107 0.894>–3.167
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for OS and DMFS.
Discussion
Our study has demonstrated that neoadjuvant chemora-
diotherapy is associated with tumour downstage with
complete pathologic response rate of 24.8 %, elevated
radical resection rate, sphincter preservation and no in-
crease in surgical complication after total mesorectal ex-
cision in patients with locally advanced rectal carcinoma.
Pathological TNM stage is strongly associated with treat-
ment outcome in these patients after neo-CRT and may
be of better prognostic significance than clinical TNM
in terms of OS, DFS. Distant metastasis remains the
main obstacle of the successful treatment for patients
with locally advanced rectal carcinoma.
In recent years, studies have been conducted to investi-
gate the influence of the postoperative pathological stage
on the prognosis of locally advanced rectal carcinoma.
Quah et al. [11] found that the postoperative pathological
stage was related to the prognosis of 331 patients with lo-
cally advanced rectal carcinoma receiving neoadjuvant
chemotherapy. In this study, pathological stage (ypT1–
2N0, ypT3–4N0, and ypN+) was significantly correlated
with DFS (P = 0.003) and OS (P = 0.000), and patients with
stage ypT0N0 or ypT1–2N0 rectal carcinoma had a better
prognosis. Park et al. [13] reported that in patients with
stage ypT0N0, ypT1–2N0, and ypT3–4/N+ rectal carcin-
oma, the 5 year OS was 93.4 %, 87.0 %, and 77.3 % (P =
0.002), respectively. The 5 year DFS was 90.5 %, 78.7 %,
and 58.5 %, respectively (p < 0.001) in 725 patients with lo-
cally advanced rectal carcinoma, and OS and DFS were
significantly different among these patients.
Thus, these investigators proposed that the pathological
stage after neoadjuvant chemotherapy was an important
predictor, and recommended postoperative adjunctive
therapeutics according to the response of rectal carcinoma
patients to chemoradiotherapy, which was also known as
individualized therapy. For example, a wait-and-see
strategy can be applied in patients with stage ypT0N0rectal carcinoma; intensified adjunctive chemotherapy
is employed in patients with stage ypT3–4/N+ colorec-
tal carcinoma. Kim et al. [14] reported that the 5 year
DFS was 65.2 % and 35.7 % in patients with stage N0
and N+ rectal carcinoma, respectively, among 114 pa-
tients with locally advanced rectal carcinoma (p =
0.002), suggesting that pathological N stage is an im-
portant predictor [15].
Our results in univariate and multivariate analyses of
prognostic factors also suggest that the pathological
stage after neoadjuvant chemoradiotherapy significantly
correlates with the prognosis of rectal carcinoma. In pa-
tients with ypT0–2N0, ypT3–4N0, and ypT0–4N+ rectal
carcinoma, the 5 year OS was 87.9 %, 75.5 % and 56.7 %
(p = 0.000), respectively; and the 5 year DFS was 74.5 %,
77.4 % and 50.5 % (p = 0.003). Stages ypT and ypN are
important predictors for disease-free survival. Clinical
TNM stage was not related to overall survival and distant
metastatic free survival although cT stage was associated
only with disease free survival in univariate analysis. Thus,
our findings together with previously reported findings in-
dicate that the postoperative pathological stages reflect the
prognosis of patients with locally advanced rectal carcin-
oma better than does clinical stage before treatment, and
it is more rational to choose and administer individualized
adjuvant therapy according to the postoperative patho-
logical stages [15].
Since pelvic lymph node status after neoadjuvant che-
moradiotherapy is an important prognostic factor in pa-
tients with locally advanced rectal carcinoma, Jwa et al.
[16] developed nomogram to improve prediction of
lymph node status after neo-CRT by analyzing pretreat-
ment ypT stage, patient age, tumor differentiation and
clinical N stage before Neo-CRT, lymphovascular inva-
sion and perineural invasion.
Stratified adjuvant therapy, performed according to
pathological stage, has been reported in patients with lo-
cally advanced rectal carcinoma after neoadjuvant chemo-
therapy. Focal dissection can be performed in patients with
locally advanced rectal carcinoma achieving pathological
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and the therapeutic efficacy is similar to that after radical
surgery [17, 18]. Moreover, this also avoids the complica-
tions and sequelae of radical surgery, and significantly im-
proves quality of life. Govindarajan et al. [19] found that
postoperative adjunctive chemotherapy had no influence
on the 5 year DFS in patients with locally advanced
colorectal carcinoma at pathological stage ypT0–2N0 after
preoperative chemoradiotherapy. Thus, the value of post-
operative adjunctive chemotherapy should be further inves-
tigated in future randomizedcontrolled trials.
In the present study, we found that the major cause of
treatment failure in patients with locally advanced rectal
carcinoma was distant metastasis. Patients with stage
ypT3–4N0 and ypT0–4N+ rectal carcinoma had the
highest rate of distant metastasis (35.7 %), which was
markedly greater than that of patients with stage ypT0–
2N0 rectal carcinoma (P < 0.001). Thus, an effective way
to improve therapeutic efficacy is to reduce distant me-
tastasis. For patients with rectal carcinoma at stage
ypT3–4N0 or stage ypT0–4N+, postoperative adjunctive
therapy should be changed to prolong the duration of
treatment or increase the dose of chemotherapeutics, or
to apply targeted therapy, which may reduce the rate of
distant metastasis and improve the survival rate.
Similar to previous studies [11], we found that clinical
stage before treatment failed to reflect the prognosis of pa-
tients with locally advanced rectal carcinoma. These were
several underlying reasons. First, the pretreatment evalu-
ation of clinical stage is different in different studies. The
accuracy and specificity of the depth of colorectal carcin-
oma invasion (T stages) for endoscopic ultrasonography
(EUS) are 94 % and 86 %, respectively [20, 21]; and for
MRI 94 % and 69 %, respectively [22–25]. The sensitivity
and specificity of determining the relationship between
carcinoma and surrounding tissues for EUS are 90 % and
75 %, respectively; for MRI 82 % and 76 %, respectively;
and for CT 55 % and 74 %, respectively [20, 26]. Thus, T
stage and N stage may not accurately reflect the disease
condition. Second, after combined use of chemotherapy
and radiotherapy, additional factors may influence the
response to treatment, such as carcinoma size, dose of ra-
diation and chemotherapeutic regimen [27]. In addition,
some molecular biological markers (such as epidermal
growth factor receptor, thymidylate synthase, p21, and
CEA) may also influence the response of colorectal carcin-
oma to chemoradiotherapy [28, 29].
Neoadjuvant chemoradiotherapy may reduce the patho-
logical stage of rectal carcinoma to a different extent in
different patients. In the present study, postoperative path-
ology confirmed that the pathological stage of rectal
carcinoma was decreased in 132 patients (62.9 %) after
neoadjuvant chemoradiotherapy, of whom patients with
rectal carcinoma at stage ypT0–2N0 accounted for43.3 %. This finding is consistent with previous reports
[13, 30–32]. Patients with rectal carcinoma at stage
ypT0–2N0 had a better prognosis.
In conclusion, neo-CRT and total mesorectal excision is
an effective treatment modality for patients with locally
advanced rectal carcinoma. The pathological stage is an
important prognostic factor, which may be used as guid-
ance for further individualized adjuvant therapy. Distant
metastasis remains obstacle for the successful treatment of
the disease. Further investigation therapeutic options are
still needed to improve clinical outcomes of locally ad-
vanced rectal carcinoma.
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